drugset / Trial / NCT03531957
Phase 2B Study to Evaluate ASN002 in Subjects With Moderate to Severe Atopic Dermatitis (RADIANT)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomized double-blind/placebo study evaluate the efficacy of ASN002 in subjects with moderate to severe atopic dermatitis (AD).
Timeline
- Start
- 2018-07-05
- Primary completion
- 2019-07-22
- Completion
- 2019-08-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gusacitinib | Small molecule | 40 mg | — |
| Subject | Gusacitinib | Small molecule | 60 mg | — |
| Subject | Gusacitinib | Small molecule | 80 mg | — |